David Nierengarten

Stock Analyst at Wedbush

(4.53)
# 322
Out of 5,182 analysts
233
Total ratings
57.71%
Success rate
19.6%
Average return

Stocks Rated by David Nierengarten

Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.27
Upside: +157.61%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53$58
Current: $43.61
Upside: +33.00%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.48
Upside: +44.23%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.56
Upside: +141.23%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.83
Upside: +90.34%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65$80
Current: $71.90
Upside: +11.27%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.40
Upside: +111.54%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $104.04
Upside: +20.15%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20$17
Current: $10.19
Upside: +66.83%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56$58
Current: $46.29
Upside: +25.30%
Reiterates: Outperform
Price Target: $30
Current: $22.48
Upside: +33.48%
Reiterates: Outperform
Price Target: $55
Current: $36.61
Upside: +50.25%
Reiterates: Outperform
Price Target: $1,000
Current: $783.74
Upside: +27.59%
Maintains: Outperform
Price Target: $4$8
Current: $7.72
Upside: +3.63%
Maintains: Outperform
Price Target: $4$5
Current: $1.31
Upside: +281.68%
Maintains: Outperform
Price Target: $90$95
Current: $86.49
Upside: +9.84%
Maintains: Outperform
Price Target: $57$65
Current: $29.17
Upside: +122.87%
Initiates: Underperform
Price Target: $110
Current: $111.90
Upside: -1.70%
Maintains: Outperform
Price Target: $110$88
Current: $68.85
Upside: +27.81%
Reiterates: Outperform
Price Target: $31
Current: $23.49
Upside: +31.97%
Reiterates: Outperform
Price Target: $25
Current: $8.79
Upside: +184.41%
Maintains: Neutral
Price Target: $9$7
Current: $13.04
Upside: -46.32%
Upgrades: Outperform
Price Target: $5$7
Current: $1.31
Upside: +434.35%
Reiterates: Outperform
Price Target: $26
Current: $13.10
Upside: +98.47%
Reiterates: Neutral
Price Target: $8
Current: $14.12
Upside: -43.34%
Downgrades: Neutral
Price Target: $80$20
Current: $33.59
Upside: -40.46%
Maintains: Outperform
Price Target: $40
Current: $66.59
Upside: -39.93%
Initiates: Outperform
Price Target: $40
Current: $76.39
Upside: -47.64%
Initiates: Outperform
Price Target: $18
Current: $10.75
Upside: +67.44%
Reiterates: Outperform
Price Target: $12
Current: $3.67
Upside: +226.98%
Maintains: Equal-Weight
Price Target: $1,400$500
Current: $1.14
Upside: +43,759.65%
Maintains: Neutral
Price Target: $105$60
Current: $8.66
Upside: +592.84%
Maintains: Outperform
Price Target: $71$75
Current: $23.99
Upside: +212.63%
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $3.76
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $10.79
Upside: -